Home › Ovarian Cancer › District of Columbia
Ovarian Cancer clinical trials in District of Columbia
7 studies for Ovarian Cancer are looking for participants at sites in District of Columbia.
Cities in District of Columbia
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
- MedStar Washington Hospital Center ( Site 0026), Washington D.C.
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT07776691Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Georgetown University Medical Center, Washington D.C.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Medstar Georgetown University Hospital, Washington D.C.
RecruitingPhase 2
Ages 18 to 99 · Women · Updated Sep 15, 2026 · NCT07023627Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's National Medical Center, Washington D.C.
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Washington D.C.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149Cancer Experience Registry (CER) for Cancer Patients and Caregivers
- Cancer Support Community Research & Training Institute, Washington D.C.
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Apr 23, 2026 · NCT02333604CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
RecruitingHealthy volunteers welcome
Ages 18 and older · Women · Updated Aug 28, 2025 · NCT05130606From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.